Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • SINGLE-CHAIN CIRCULAR RNA AND METHOD OF PRODUCING THE SAME
    Publication number: 20180073020
    Abstract: The present invention relates to a single-chain circular RNA having a sustained or slow-releasing RNA interference effect, characterized in that the single-chain circular RNA comprises a sense strand sequence, an antisense strand sequence complementary to the sense strand sequence, identical or different two loop sequences between the sense strand and the antisense strand, connecting both strands, wherein the sense strand and the antisense strand are paired to form a stem.
    Type: Application
    Filed: August 21, 2017
    Publication date: March 15, 2018
    Applicants: Riken, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Abe, Yoshihiro Ito, Naoko Abe, Hidekazu Toyobuku
  • METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF
    Publication number: 20180065931
    Abstract: The present invention provides a method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof, the method including the step of heating hydroquinone and 4-(4-trifluoromethoxyphenoxy)piperidine. This method can produce 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof in an industrially advantageous manner.
    Type: Application
    Filed: March 25, 2016
    Publication date: March 8, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro MIYAKE, Aya ASAHINA, Takahiro OKADA
  • INJECTABLE PREPARATION
    Publication number: 20180055941
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 1, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
  • ORAL FORMULATION
    Publication number: 20180055840
    Abstract: Provided are an oral formulation capable of improving easy administrability and showing good preservation stability, and a substrate for oral formulation. An oral formulation containing a medicament; sugar alcohol; one or more kinds of hydrophilic polysaccharides selected from the group consisting of acacia, pullulan and maltodextrin; a gelling agent; and water, and a substrate for oral formulation, which contains sugar alcohol; the above-mentioned hydrophilic polysaccharides; a gelling agent; and water.
    Type: Application
    Filed: October 27, 2017
    Publication date: March 1, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Taro IWAMOTO, Nobuyuki KURAHASHI, Yoshikazu OKA, Chikako TAKEDA
  • COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
    Publication number: 20180042923
    Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophea-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 15, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
  • PRIMER SET AND METHOD FOR AMPLIFYING EXONS OF PKD1 GENE AND PKD2 GENE
    Publication number: 20180037955
    Abstract: The present invention provides a means for efficiently amplifying the exons of PKD1 and PKD2 genes, and a primer set that can amplify all the exons of PKD1 and PKD2 genes under a single set of PCR conditions.
    Type: Application
    Filed: November 13, 2015
    Publication date: February 8, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kiyonori KATSURAGI, Moritoshi KINOSHITA, Daisuke KOGA, Ryo HIGASHIYAMA
  • PATHOLOGY DETERMINATION ASSISTANCE DEVICE, METHOD AND STORAGE MEDIUM
    Publication number: 20180032673
    Abstract: The device for assisting determination of pathology of a polycystic kidney disease according to the present invention has an extraction means 21 for extracting gene mutation information in a region related to polycystic kidney disease using sequence data showing gene sequences of a test subject; an acquisition means 22 for acquiring, using the extracted gene mutation information, medical information corresponding to the extracted gene mutation from a plurality of databases in which gene mutation and medical information are associated with each other; and a list display means 23 for displaying a list containing the extracted gene mutation information and the obtained medical information.
    Type: Application
    Filed: September 3, 2014
    Publication date: February 1, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Moritoshi KINOSHITA, Ryo HIGASHIYAMA, Daisuke KOGA
  • Tablet Comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1 -yl)butoxy]-1H-Quinolin-2-One or a Salt Thereof
    Publication number: 20180008600
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu INOUE
  • PHARMACEUTICAL PREPARATION COMPRISING BREXPIPRAZOLE AND SUBSTITUTED BETA-CYCLODEXTRIN
    Publication number: 20180008599
    Abstract: Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted ?-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted ?-cyclodextrin.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya HASEGAWA, Hidekazu TOYOBUKU
  • METHOD FOR QUANTITATIVE MEASUREMENT OF GASTRIC ACIDITY USING 13C CARBONATE SALT
    Publication number: 20180003695
    Abstract: The present invention provides a method for measuring the gastric acidity of a mammal using a 13C-labeled carbonate compound. Specifically, the present invention relates to a method for measuring the gastric acidity of a mammal including the following steps: (1) using, as a test sample, expired air of a mammalian subject excreted at any point in time within 30 minutes after oral administration of a predetermined amount of a 13C-labeled carbonate compound, measuring behavior of 13CO2 in the expired air; (2) comparing the behavior of 13CO2 (measured 13CO2 behavior) obtained in step (1) with the behavior of corresponding 13CO2 (reference 13CO2 behavior) that has been obtained beforehand in a control mammal; and (3) determining the gastric acidity of the mammalian subject based on a difference between the reference 13CO2 behavior and the measured 13CO2 behavior obtained above.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 4, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Makoto INADA, Jun-ichi KUNIZAKI, Kazuki TOBITA, Suguru AKAMATSU, Shinji llZUKA
  • Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
    Publication number: 20170368060
    Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Application
    Filed: September 6, 2017
    Publication date: December 28, 2017
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Hiroshi YAMASHITA, Nobuaki ITO, Shin MIYAMURA, Kunio OSHIMA, Jun MATSUBARA, Hideaki KURODA, Haruka TAKAHASHI, Satoshi SHIMIZU, Tatsuyoshi TANAKA
  • Method for measuring anti-WT1 antibody
    Patent number: 9851356
    Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 26, 2017
    Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Haruo Sugiyama, Yusuke Oji, Kiyonori Katsuragi, Hideaki Tanaka, Shinji Sogo, Yoshihiro Goto, Yasukazu Ohmoto, Husako Iwata
  • Piperazine-substituted benzothiophenes for treatment of mental disorders
    Patent number: 9839637
    Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: December 12, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Yamashita, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Hideaki Kuroda, Haruka Takahashi, Satoshi Shimizu, Tatsuyoshi Tanaka
  • Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines
    Patent number: 9834576
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: December 5, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Water-soluble benzoazepine compound and its pharmaceutical composition
    Patent number: 9809609
    Abstract: The present invention provides a benzoazepine compound represented by following general formula (1): or a salt thereof, wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and can be suitably used for injections.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: November 7, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Makoto Komatsu, Fumitaka Goto, Yasuhiro Menjo, Keigo Yamada, Takakuni Matsuda, Yusuke Kato
  • METHOD FOR EVALUATING EFFICACY OF CHEMORADIOTHERAPY AGAINST SQUAMOUS CELL CARCINOMA
    Publication number: 20170292955
    Abstract: A method for evaluating an efficacy of a chemoradiotherapy against squamous cell carcinoma comprises the following steps (a) to (c): (a) detecting an expression level of at least one gene selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject; (b) comparing the expression level detected in the step (a) with a reference expression level of the corresponding gene; and (c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).
    Type: Application
    Filed: September 24, 2015
    Publication date: October 12, 2017
    Applicants: NATIONAL CANCER CENTER, KYOTO UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki SASAKI, Kazuhiko AOYAGI, Manabu MUTO, Hiroo TAKAHASHI
  • Controlled release sterile injectable aripiprazole formulation and method
    Patent number: 9763935
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: September 19, 2017
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar
  • ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE
    Publication number: 20170258723
    Abstract: [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 14, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Haruka YOSHIDA, Toshiaki TANIGUCHI, Tadashi MUKAI
  • HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS
    Publication number: 20170253576
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Application
    Filed: August 28, 2015
    Publication date: September 7, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi SHIMIZU, Yoshikazu KAWANO, Shunpei ISHIKAWA, Yukitaka UEMATSU, Toshio SHINOHARA, Motohiro ITOTANI, Yoshikazu HARAGUCHI, Isao TAKEMURA, Atsunori KANESHIGE, Yuya NAKAI, Norimitsu HARIGUCHI, Yohei HAYASHI, Makoto MATSUMOTO
  • Transpulmonary liposome for controlling drug arrival
    Patent number: 9750694
    Abstract: An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. By modifying the surface of a liposome using a terminal hydrophobized polyvinyl alcohol and/or chitosan, retention of drugs or genes encapsulated in the liposome on the surface of lung tissue and transfer of drugs or genes into lung tissue can be properly modulated, and thus in vivo behavior can be controlled.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 5, 2017
    Assignees: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hirofumi Takeuchi, Koji Nakano, Hidekazu Toyobuku